mucin

MUC1, mucin core is a type I transmembrane glycoprotein that is characterized by its overexpression and abnormal glycosylation in carcinoma cells. It specifically binds to domain 1 of ICAM-1.

1. Obtusifolin has antioxidant properties and improves chemically induced diabetes and its complications by modulation of oxidative stress. 2. Obtusifolin suppresses phthalate esters-mediated bone resorption, thus may be a novel anti-breast-cancer bone me

Guaifenesin (Guaiphenesin) is an expectorant that also has some muscle relaxing action. It is used in many cough preparations.

Gefarnate is a synthetic compound used for the treatment of gastric ulcers,and also used in the treatment of dry eye syndrome.

M0324 is a novel MUC-1 conditional CD40 agonist composed of an anti-MUC-1 IgG and two identical CD40-targeting camelid VHH domains, designed to selectively activate immune cells in the context of tumor cells with high MUC-1 expression.

Fudosteine is a novel mucoactive agent and a MUC5AC mucin hypersecretion inhibitor.

Gatipotuzumab (PankoMab) is a novel humanized monoclonal antibody conjugated to the tumor-associated epitope of mucin 1 (TA-MUC1) with potential anti-tumor activity for the study of recurrent epithelial ovarian cancer.

Ac5GalNTGc, an analog of hexosamine, inhibits mucin-type O-linked glycosylation biosynthesis [1].

Anti-CA6 Antibody (huDS6) is an antibody that specifically targets the sialic acid sugar epitope associated with mucin 1 (CA6). It is utilized in the synthesis of antibody-drug conjugates (ADCs).

Clivatuzumab MMAE is an ADC consisting of a humanized monoclonal antibody against MUC1 (mucin) and the anti-mitotic cytotoxin MMAE for pancreatic cancer.

Anti-MUC17 Antibody is a humanized monoclonal antibody expressed in CHO cells targeting the transmembrane mucin MUC17 (also known as MUC3G). This product specifically recognizes the extracellular domain of MUC17. MUC17 is overexpressed in various gastrointestinal tumors, particularly gastric and colorectal cancers. The antibody binds to MUC17 on the cell surface, mediating antibody-dependent cellular cytotoxicity (ADCC), and serves as a vehicle for the targeted delivery of conjugated therapeutic payloads (as in ADC research) into tumor cells.

MUC5AC motif peptide, a 16-amino acid fragment of mucin 5, is a key component in the study of glycoproteins and their biological functions.

Fexlamose is an interventional nebulization solution with mucolytic properties, intended for research in chronic obstructive pulmonary disease (COPD).

Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.

L-GO-203 TFA is a potent inhibitor of the MUC1-C oncoprotein, functioning as an anticancer peptide that targets intracellular proteins [1].

Sofituzumab is a humanised monoclonal antibody targeting the MUC16 protein, commonly used in the synthetic ADC Sofituzumab vedotin, which can be used to treat ovarian cancer and pancreatic cancer.

Sontuzumab (AS1402) is a humanized monoclonal antibody targeting MUC1 that binds to the extracellular MUC1 peptide sequence PDTR (Kd≈1 nM) and can be used for breast cancer research.

Sofituzumab vedotin is an anti-MUC16 antibody-drug conjugate (ADC) containing MMAE and a protease-cleavable linker, which can be used in cancer research.

Minretumomab (CC-49) is a mouse monoclonal antibody targeting TAG-72 (tumour-associated glycoprotein 72), optimised from the B72.3 antibody, and can be used for research into breast cancer, colon cancer, lung cancer, and pancreatic cancer.

Clivatuzumab tetraxetan (IMMU107), a humanized anti-MUC1 monoclonal antibody, exhibits anti-tumor activity and holds potential for research in metastatic pancreatic cancer [1] [2].

Oregovomab is a highly specialized murine monoclonal antibody target the tumor-associated antigen CA125 (MUC16), induction of robust anti-idiotypic antibody responses and T-cell mediated anti-tumor immunity by forming immune complexes across various preclinical experimental models.

TAB-004 is a human monoclonal antibody targeting MUC1. It specifically identifies the tMUC1 present in all major subtypes of breast cancer without affecting normal breast epithelial cells. Additionally, TAB-004 is applicable for research on triple-negative breast cancer (TNBC).

BTH1704 is a human monoclonal antibody targeting MUC1. It facilitates the killing of iC3b-opsonized tumor cells by leukocytes triggered by PGG. BTH1704 is applicable in studies on pancreatic cancer and breast cancer.

Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA is an antibody-drug conjugate (ADC) composed of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked with the MC-Vc-PAB-DMEA-PEG2 connector and the DNA alkylator Duocarmycin SA. This compound is utilized in cancer research.